Jonathan C. Javitt is Director & 10% Owner at NRX Pharmaceuticals, Inc. (NRXP). They have made 7 open-market trades across 2 companies since 2008, most recently 2024-12-17.
CIK 0001303782
5 open-market purchases totalling $6.1M since 2022, against 2 sales. Across 5 scored buys the stock is up 1.9% at ninety days, and 3.5 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 20% | 20% | 40% |
| Avg Move | -8.4% | +13.1% | +1.9% |
| Alpha | -5.0% | +16.7% | +3.5% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NRXP | BUY | 2024-12-17 | 2024-12-18 | $1.17 | $47K | +41.0% | +157.1% | +41.0% |
| NRXP | BUY | 2023-08-23 | 2023-08-24 | $0.33 | $33K | -20.3% | -30.8% | -10.9% |
| NRXP | BUY | 2023-08-22 | 2023-08-23 | $0.32 | $64K | -5.3% | -11.7% | +1.4% |
| NRXP | SELL | 2022-12-07 | 2022-12-09 | $1.00 | $400K | -17.2% | -13.4% | -47.0% |
| NRXP | BUY | 2022-06-01 | 2022-06-02 | $0.58 | $116K | -28.8% | -24.6% | -11.0% |
| NRXP | BUY | 2022-06-01 | 2022-06-02 | $58.00 | $5.8M | -28.8% | -24.6% | -11.0% |
| BCLI | SELL | 2008-08-27 | 2008-08-28 | $0.25 | $10K | -32.9% | +3.1% | +3.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.